Pharmaceuticals, Biotechnology and Life Sciences
Hemogenyx Pharmaceuticals has signed a research agreement through is subsidiary Immugenyx, to develop humanized mice as a tool for drug development and testing, including with a global pharmaceutical company, whose identity must remain hidden at its request.
Vladislav Sandler, Chief Executive Officer of Hemogenyx Pharmaceuticals, said the potential of the ApbHC, a new generation of our humanized mice, which has allowed the company to rapidly obtain in vivo data on the efficacy of the company’s CDX antibodies against AML.
Hemogenyx and Orgenesis have entered into collaboration on the further development of Human Postnatal Hemogenic Endothelial Cell technology
Hemogenyx Pharmaceuticals has ensured a continuation of a pact with a major US biotechnology company for filing of a provisional patent…
Hemogenyx Pharmaceuticals has appointed a pioneer in modern cancer research H. Michael Shepard to its Scientific Advisory Board, praising his work…
Hemogenyx Pharmaceuticals has picked LakePharma as its service provider for the development and manufacturing of Hemogenyx’s lead product, CDX bi-specific…